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ABSTRACT
Cholangiocarcinoma is a malignancy arising from the biliary tract epithelial cells
with poor prognosis. Tumor infiltrating lymphocytes (TIL)s and programmed cell
death receptor ligand 1 (PD-L1) have a prognostic impact in various solid tumors.
We aimed to investigate TILs and PD-L1 expression and their clinical relevance in
cholangiocarcinoma. Tumor samples from 44 patients with resected and histologically
verified extrahepatic cholangiocarcinoma were evaluated for CD8, CD45RO and PDL1 expression, and their correlations with clinicopathological data and survival data
were analyzed. Total 44 extrahepatic cholangiocarcinoma tissues were evaluated.
CD8+ tumor infiltrating lymphocytes (TIL)s were observed in 30 (68%) tumors.
Among them, 14 had CD8+CD45RO+ TILs. PD-L1 was expressed on cancer cells in 10
(22.7%) tumors in 34 evaluable extrahepatic cholangiocarciniomas. The presence of
CD8+ TILs or CD8+CD45RO+ TILs was not associated with clinical staging or tumor
differentiation. Extrahepatic cholangiocarcinoma with CD8+CD45RO+ TILs had longer
overall survival (OS) on univariate (P = 0.013) and multivariate (P = 0.012) analysis.
Neither CD8+TIL nor PD-L1 expression on cancer cells correlated significantly with
OS. These results add to the understanding of the clinical features associated with
CD8 TILs and PD-L1 expression in extrahepatic cholangiocarcinoma, and they support
the potential rationale of using PD-1 blockade immunotherapy in cholangiocarcinoma.

INTRODUCTION

treatment of recurrent or metastatic disease is quite
challenging. Although gemcitabine plus cisplatin has
demonstrated a significant antitumor activity as firstline therapy for metastatic cholangiocarcinoma [3], new
effective therapeutic approaches are needed for further
improvement of clinical outcome.
Rapid advances in tumor immunology have
improved our understanding of key regulators that mediate
antitumor T cell responses, leading to the development
of new immunotherapeutic approaches targeting
programmed cell death 1 (PD-1). PD-1 is one of the
negative immune regulators which play an essential role in

Cholangiocarcinoma is a rare cancer originating
from the epithelial cells of the intrahepatic and extrahepatic
bile ducts. Extrahepatic cholangiocarcinoma is further
characterized as perihilar and distal cholangiocarcinoma.
Cholangiocarcinoma is an uncommon malignancy
accounting for approximately 3% of all gastrointestinal
tumors [1]. However, it is a very aggressive group of
malignancies with overall dismal prognosis. The 5 year
survival rate is only 10% [2]. While local treatment such
as surgical resection is effective for localized disease,
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immunosuppression of antitumor immunity in local tumor
environment. PD-1 is expressed on the surface of activated
T cells, and its ligand, PD-L1 is broadly displayed on
antigen presenting cells and tumor cells [4]. The ligation
of PD-1 and PD-L1 inhibits T cell proliferation and
activation and induces apoptosis of tumor antigen-specific
T cells to inhibit antitumor immunity and escape immune
surveillance [4]. Emerging clinical data have demonstrated
durable clinical activity and safety of PD-1 blockade agents
in diverse malignancies including melanoma, non-small
cell lung cancer, renal cell carcinoma, urothelial cancer,
Hodgkin lymphoma, head and neck cancer and mismatch
repair deficient colorectal cancer [5]. The remarkable
success of PD-1 blockade immunotherapy has led to
the extensive research effort to discover prognostic and
predictive markers and to evaluate potential therapeutic
activity of antiPD-1 immunotherapy in other malignancies.
Recent clinical data have demonstrated that presence of
CD8 tumor infiltrating lymphocytes (TILs) and PD-L1
expression in tumor microenvironment have not only
prognostic implication but also predict clinical response to
PD-1 blockade immunotherapy in a number of malignant
tumors [6, 7]. However, very little is known about the
immune microenvironment of cholangiocarcinoma.
We have performed a retrospective analysis of a
single institution cohort of extrahepatic cholangiocarcinoma
patients with expression of TILs and PD-L1 in tumor
microenvironment to improve our understanding of
their significance and to provide potential rationale for
the utility of PD-1 blockade immunotherapy option in
cholangiocarcinoma.

was evaluated only in 34 tumors (perihilar: 9, distal: 25) due
to lack of sufficient tumor tissues in the remaining samples.
While PD-L1 was expressed in 32 (94.1%) tumor samples,
PD-L1 expression on cancer cells was observed in only
10 tumors (22.7%). All 10 tumors with PD-L1 expressing
cancer cells had CD8+ TIL infiltration. Two of them are
perihilar and the rest are distal disease. Previous reports
suggested CD45RO expressing immune cell infiltration
as an independent prognostic marker in gastrointestinal
cancer including colorectal and gastric cancer [8, 9]. Tumor
infiltrating CD45RO+ immune cells were also evaluated, and
they were detected in 21 (47.7%) of cholangiocarcinomas.
Fourteen tumors have CD8+CD45RO+ T cells (memory
CD8 T cells) in 21 extrahepatic tumors with CD45RO+
infiltrating immune cells.

Clinical and pathologic characteristics associated
with tumor-immune cell infiltration
The relationship between clinicopathological features
and immune cell infiltration was analyzed (Supplementary
Figure 1). The presence of CD8+ TILs or CD8+CD45RO+
TILs was not associated with clinical staging or tumor
differentiation in extrahepatic cholangiocarcinoma. No
correlation between PD-L1 expression and clinical staging
or tumor differentiation was observed (data not shown).

Prognostic value of tumor-immune cell
infiltration and PD-L1 expression
To determine prognostic value of immune cells
infiltration, correlation between immune cells infiltration
and clinical outcome was examined. While no significant
correlation was observed between CD8+ TILs and relapse
free survival (RFS) or overall survival (OS), patients with
CD45RO+ infiltrating immune cells had longer relapse
free survival and overall survival in cholangiocarcinoma
(median RFS: 23.3 mo vs 12.5 mo, P = 0.006; median
OS: 49.7 mo vs 18.9mo, P = 0.003) (Figure 2). To further
evaluate clinical outcomes of tumors with CD8+ TILs, CD8+
TILs were further subgrouped into CD8+ TILs high (≥100
positive cells per high power field) and low (<100 positive
cells per high power field) or CD8+CD45RO+ TILs and
CD8+CD45RO– TILs. While high number of CD8+ TILs
infiltration did not have any prognostic value (Supplementary
Figure 2), significant correlation between the presence of
CD8+CD45RO+ TIL and RFS or OS (median RFS: 45.9 mo
vs 12.2 mo, P = 0.004; median OS: 49.7 mo vs 20.2 mo,
P = 0.019) was observed (Figure 2). PD-L1 expression on
cancer cells was not associated with RFS or OS (Figure 3).
For evaluation of the relationship between the level of PDL1 expression and clinical outcome, the PD-L1 expressing
tumors were divided into two groups (high vs low) using
cutoff value of 5%. No correlation between the level of PDL1 expression and RFS or OS was observed (Supplementary
Figure 3).

RESULTS
Baseline characteristics
A total of 44 patients who underwent surgical
resection of extrahepatic cholangiocarcinoma were
identified (Table 1). The median age of the patients was 67
years (range 42–86) and 52.3% were male. Eleven (25%)
patients had perihilar and 33 (75%) had distal tumor.
A majority of tumors (84.0%) were well to moderately
differentiated and R0 resection was done on 37 (84.1%)
patients.

TIL and PD-L1 expression in tumor
microenvironment
Tumor microenvironment was evaluated using
immunohistochemical staining with anti-CD8 and PD-L1
antibodies. PD-L1 expressing tumor and immune cells and
CD8+ lymphocytes were identified in intratumoral and
peritumoral area (Figure 1). Intratumoral CD8+ TILs were
observed in 30 (68.2%) tumor samples. While 10 (90.9%)
out of 11 perihilar tumors have intratumoral CD8+TIL, 20
(60.6%) out of 33 distal tumors have it. PD-L1 expression
www.oncotarget.com
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Table 1: Patients characteristics
Variable

N = 44

Median Age (range)
Gender
Male (%)
Female (%)
Location
Perihilar (%)
Distal (%)
Stage
I (%)
II (%)
III (%)
Differentiation
Well (%)
Moderate (%)

67 (42–86)
23 (52.3%)
21 (47.7%)
11 (25%)
33 (75%)
12 (27.3%)
25 (56.8%)
7 (15.9%)
13 (29.5%)
24 (54.5%)

Poorly (%)

7 (15.9%)

Surgical Resection

R0 (%)

37 (84.1%)

R1 (%)

5 (11.4%)

R2 (%)

2 (4.5%)

Figure 1: Representative immunohistochemical staining of CD8, CD45RO and PD-L1. IT: intratumoral area, PT: peritumoral
area.
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Univariate and multivariate analysis

DISCUSSION

Univariate and multivariate Cox regression
modeling was performed to identify significant predictors
of OS including age, gender, resection, differentiation,
clinical stage, CD8+ TILs, CD8+CD45RO+ TILs and
CD45RO+ infiltrating immune cells (Table 2). Resection,
stage, CD8+CD45RO+ TILs and CD45RO+ infiltrating
immune cells were associated with survival on univariate
analysis. On multivariate analysis, the presence of
CD8+CD45RO+ TILs (HR 0.29, 95% CI 0.11–0.76,
P = 0.012) as well as resection and stage were independent
prognostic markers. While the presence of CD45RO+
infiltrating immune cells was associated with improved
survival on univariate analysis, it was not an independent
prognostic marker on multivariate analysis.

The tumor immune microenvironment is a
potentially powerful predictive and prognostic marker
of immunotherapy. The recent success of PD-1 blockade
immunotherapy has led to extensive studies to discover
predictive markers in tumor microenvironment of
several malignancies. However, only limited data of
tumor immune microenvironment are available in
cholangiocarcinoma. While the presence of TILs and PDL1 expression have been identified in cholangiocarcinoma
[10, 11], their clinical associations have not been fully
elucidated due to the rarity of the disease. In this study, we
evaluated tumor immune microenvironment of 44 resected
extrahepatic cholangiocarcinoma tumor samples with the
clinical outcome. Our study focused on CD8 TILs and PD-

Figure 2: Kaplan–Meier analysis of relapse free survival and overall survival based on the presence of CD8, CD45RO
or CD8CD45RO tumor infiltrating lymphocytes.

Figure 3: Kaplan–Meier analysis of relapse free survival and overall survival by PD-L1 expression status on tumor
cells.
www.oncotarget.com
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Table 2: Univariate and multivariate analysis using Cox Proportional Hazards Model
Univariate
Variables
HR
95% CI
P value
HR
Age
Gender

1.01

0.97–1.04

0.67

Male
Female
Resection

0.81

0.39–1.70

0.58

R0
R1
R2
Differentiation

0.37
4.9

0.09–1.57
1.09–21.97

0.18
0.038

Well
Moderately
Poorly
Stage

1.64
3.8

0.73–3.67
0.88–16.46

0.23
0.08

1.9
3.54
0.83
0.3
0.34

0.80–4.47
1.19–10.56
0.41–1.70
0.12–0.78
0.16–0.71

0.14
0.023
0.61
0.013
0.005

I
II
III
CD8
CD8CD45RO
CD45RO

Multivariate
95% CI

P value

7.66

1.45–40.59

0.017

4.73

1.49–14.99

0.008

0.29
0.65

0.11–0.76
0.24–1.75

0.012
0.39

Abbreviation: CI: confidence interval.
L1 expression as they can provide potential rationale for
the usage of PD-1 blockade immunotherapy.
In our study, intratumoral CD8 TILs were observed
in 68% of extrahepatic cholangiocarcinomas which are
similar to the frequency observed in the previous report
[10]. Interestingly, only CD8+CD45RO+ TIL but not
CD8+ TIL had prognostic significance. The presence
of memory (CD45RO+) CD8 TILs has been reported
as a favorable prognostic marker in several cancers
[12]. Our results did not demonstrate prognostic value
of CD8 TILs. This was in contrast with other cancers
where improved survival was associated with CD8 TILs
[13]. One possible explanation for the discrepancy is the
presence of immune suppressive cells such as regulatory
T cells (Treg)s and suppressor CD8 T cells. Previous
meta-analysis data showed CD8/Tregs (FOXP3+) ratio
produced more impressive hazard ratio than CD8 TILs
alone [13], and Tregs but not CD8 TILs were reported as
independent prognostic markers in cholangiocarcinoma
[14]. In addition, recent data demonstrated a majority
of CD8 suppressor cells do not express CD45RO [15],
which may explain our result that memory type CD8 TIL
(CD8+CD45RO+) but not CD8 TIL was associated with
significant improvement in OS. Unfortunately, we could
not examine FOXP3 due to insufficient tumor samples.
www.oncotarget.com

PD-L1 expression was observed on both immune
cells and cancer cells. Total 22.7% of tumors had PDL1 expression on their cancer cells which is relatively
similar to the rate observed in a previous report (29.6%)
[11]. However, it is higher than other cholangiocarcinoma
studies (9% and 11.6%) [10, 16]. The discordance of
PD-L1 expression may be explained by different antiPD-L1 antibodies and different cut-off value of PD-L1
staining positivity in each study. In addition, different
cholangiocarcinoma patient population in each study
may contribute to the discrepancy since PD-L1 is highly
expressed on special subtypes of cholangiocarcinomas such
as intrahepatic lymphoepithelioma like cholangiocarcinoma
[17], occupational cholangiocarcinoma [18] and liver
fluke related cholangiocarcinoma [19] compared with
conventional cholangiocarcinoma.
We did not observe any correlation between PD-L1
expression on cancer cells and overall survival which is
consistent with previous reports [11, 16, 19]. However,
other studies suggested PD-L1 expression as a negative
prognostic factor in cholangiocarcinoma [20, 21]. This
discrepancy may be explained by small sample size of
each study ranging from 27–70 cases. In addition, they
were all retrospective studies conducted mainly from
single institutions.
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In our study, we combined perihilar and distal
tumors to extrahepatic cholangiocarcinoma due to small
sample size, which did not allow direct comparison of
each subtype of cholangiocarcinoma.
In conclusion, our study reports the analysis of
tumor microenvironment in patients diagnosed with
extrahepatic cholangiocarcinoma. Our results suggest
that CD8 memory (CD8+CD45RO+) TILs but not CD8
TILs correlate with a favorable prognosis in extrahepatic
cholangiocarcinoma. In addition, our study show
that cholangiocarcinoma cancer cells express PD-L1
which is suggested as a potential predictive marker of
PD-1 blockade immunotherapy. It is unclear if any of
these markers has predictive value on the response to
immunotherapy but hopefully ongoing immunotherapy
trials will shed some light on these questions.

survival, and Log-rank testing was performed to determine
the significance of observed difference. COX proportional
hazard regression was used for multivariate analysis. All
statistical analyses were performed using IBM SPSS
Statistics 24. All statistical tests used a significance level
of 5%.

Abbreviations
OS: overall survival; PD-1: programmed cell death
receptor; PD-L1: programmed cell death receptor ligand
1; RFS: relapse free survival; TIL: tumor infiltrating
lymphocyte; Treg: regulatory T cell.
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MATERIALS AND METHODS
Patient selection and clinical data collection
Under an Institutional Review Board-approved
protocol, formalin-fixed paraffin-embedded tumor samples
from patients with resected and histologically verified
extrahepatic cholangiocarcinoma at Moffitt Cancer
Center, between 1990 and 2015 were obtained. Patient
demographics, primary tumor characteristics, treatment
received and overall survival were collected by chart review
retrospectively.

CONFLICTS OF INTEREST
Richard Kim received honorarium from Lilly. The
other authors report no conflicts of interest for this work.

REFERENCES

Immunohistochemical staining
Tissue sections (4µm thick) were immersed in
citrate buffer solution for antigen retrieval and boiled in
microwave for 10 min and washed in buffer solution. They
were incubated with primary antibody including anti-CD8
(C8/144B, DAKO), anti-CD45RO (UCHL1, DAKO)
and the anti-PDL1 mouse IgG1 (clone 5H1; Thompson)
antibodies for 1 hr at room temperature and then washed
in buffer solution. After 1 hr of incubation in the secondary
antibody, the sections were incubated with streptavidinbiotin-complex (DAKO). Appropriate positive and
negative controls were used. Stained tumor samples
were reviewed and enumerated by a GI pathologist. For
estimation of positive reaction, only the strongly stained
nuclei were counted as a percentage of all tumor nuclei.
Less than 1% were estimated as negative. Samples with
greater than 1% of cells exhibiting strong nuclear staining
were considered positive.

1.

Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management
of cholangiocarcinoma. Gastroenterology. 2013; 145:1215–
29. https://doi.org/10.1053/j.gastro.2013.10.013.

2.

Everhart JE, Ruhl CE. Burden of digestive diseases in the
United States Part III: Liver, biliary tract, and pancreas.
Gastroenterology. 2009; 136:1134–44. https://doi.
org/10.1053/j.gastro.2009.02.038.

3.

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney
A, Maraveyas A, Madhusudan S, Iveson T, Hughes S,
Pereira SP, Roughton M, Bridgewater J; the ABC-02
Trial Investigators. Cisplatin plus gemcitabine versus
gemcitabine for biliary tract cancer. N Engl J Med. 2010;
362:1273–81. https://doi.org/10.1056/NEJMoa0908721.

4.

Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer:
past, present, and future. J Clin Invest. 2015; 125:3384–91.
https://doi.org/10.1172/JCI80011.

5.

Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM,
Topalian SL. Antagonists of PD-1 and PD-L1 in Cancer
Treatment. Semin Oncol. 2015; 42:587–600. https://doi.
org/10.1053/j.seminoncol.2015.05.013.

6.

Tumeh PC, Harview CL, Yearley JH, Shintaku IP,
Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G,
Ciobanu V, West AN, Carmona M, Kivork C, et al.

Statistical methods
Fisher’s exact test was used to assess the association
between TILs and clinicopathological characteristics. The
association between expression of CD8/CD45RO or PDL1 and survival was investigated using Kaplan-Meier
www.oncotarget.com

23371

Oncotarget

PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 2014; 515:568–71. https://doi.
org/10.1038/nature13954.

Prognostic impact of tumour-infiltrating immune cells on
biliary tract cancer. Br J Cancer. 2013; 109:2665–74. https://
doi.org/10.1038/bjc.2013.610.

7. Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and Survival
in Solid Tumors: A Meta-Analysis. PLoS One. 2015; 10:
e0131403. https://doi.org/10.1371/journal.pone.0131403.

15. Suzuki M, Jagger AL, Konya C, Shimojima Y, Pryshchep S,
Goronzy JJ, Weyand CM. CD8+CD45RA+CCR7+FOXP3+
T cells with immunosuppressive properties: a novel subset
of inducible human regulatory T cells. J Immunol. 2012;
189:2118–30. https://doi.org/10.4049/jimmunol.1200122.

8. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A,
Molidor R, Mlecnik B, Kirilovsky A, Nilsson M,
Damotte D, Meatchi T, Bruneval P, Cugnenc PH, et al.
Effector memory T cells, early metastasis, and survival
in colorectal cancer. N Engl J Med. 2005; 353:2654–66.
https://doi.org/10.1056/NEJMoa051424.

16. Walter D, Herrmann E, Schnitzbauer AA, Zeuzem S, Hansmann
ML, Peveling-Oberhag J, Hartmann S. PD-L1 expression
in extrahepatic cholangiocarcinoma. Histopathology. 2017;
71:383–392. https://doi.org/10.1111/his.13238.

9. Wakatsuki K, Sho M, Yamato I, Takayama T, Matsumoto S,
Tanaka T, Migita K, Ito M, Hotta K, Nakajima Y. Clinical
impact of tumor-infiltrating CD45RO(+) memory T cells
on human gastric cancer. Oncol Rep. 2013; 29:1756–62.
https://doi.org/10.3892/or.2013.2302.

17. Wang L, Dong H, Ni S, Huang D, Tan C, Chang B,
Sheng W. Programmed death-ligand 1 is upregulated in
intrahepatic lymphoepithelioma-like cholangiocarcinoma.
Oncotarget. 2016; 7:69749–59. https://doi.org/10.18632/
oncotarget.11949.

10. Fontugne J, Augustin J, Pujals A, Compagnon P, Rousseau B,
Luciani A, Tournigand C, Cherqui D, Azoulay D,
Pawlotsky JM, Calderaro J. PD-L1 expression in perihilar
and intrahepatic cholangiocarcinoma. Oncotarget. 2017;
8:24644–51. https://doi.org/10.18632/oncotarget.15602.

18. Sato Y, Kinoshita M, Takemura S, Tanaka S, Hamano G,
Nakamori S, Fujikawa M, Sugawara Y, Yamamoto T,
Arimoto A, Yamamura M, Sasaki M, Harada K, et al.
The PD-1/PD-L1 axis may be aberrantly activated in
occupational cholangiocarcinoma. Pathol Int. 2017;
67:163–70. https://doi.org/10.1111/pin.12511.

11. Sabbatino F, Villani V, Yearley JH, Deshpande V, Cai L,
Konstantinidis IT, Moon C, Nota S, Wang Y, Al-Sukaini A,
Zhu AX, Goyal L, Ting DT, et al. PD-L1 and HLA Class
I Antigen Expression and Clinical Course of the Disease
in Intrahepatic Cholangiocarcinoma. Clin Cancer Res.
2016; 22:470–8. https://doi.org/10.1158/1078-0432.
CCR-15-0715.

19. Sangkhamanon S, Jongpairat P, Sookprasert A,
Wirasorn K, Titapun A, Pugkhem A, Ungareevittaya P,
Chindaprasirt J. Programmed Death-Ligand 1 (PDL1) Expression Associated with a High Neutrophil/
Lymphocyte Ratio in Cholangiocarcinoma. Asian Pac J
Cancer Prev. 2017; 18:1671–4. https://doi.org/10.22034/
APJCP.2017.18.6.1671.

12. Jia Q, Yang Y, Wan Y. Tumor-infiltrating memory
T-lymphocytes for prognostic prediction in cancer patients:
a meta-analysis. Int J Clin Exp Med. 2015; 8:1803–13.

20. Ma K, Wei X, Dong D, Wu Y, Geng Q, Li E. PD-L1 and
PD-1 expression correlate with prognosis in extrahepatic
cholangiocarcinoma. Oncol Lett. 2017; 14:250–6. https://
doi.org/10.3892/ol.2017.6105.

13. Gooden MJ, de Bock GH, Leffers N, Daemen T,
Nijman HW. The prognostic influence of tumour-infiltrating
lymphocytes in cancer: a systematic review with metaanalysis. Br J Cancer. 2011; 105:93–103. https://doi.
org/10.1038/bjc.2011.189.

21. Gani F, Nagarajan N, Kim Y, Zhu Q, Luan L, Bhaijjee F,
Anders RA, Pawlik TM. Program Death 1 Immune
Checkpoint and Tumor Microenvironment: Implications
for Patients With Intrahepatic Cholangiocarcinoma. Ann
Surg Oncol. 2016; 23:2610–7. https://doi.org/10.1245/
s10434-016-5101-y.

14. Goeppert B, Frauenschuh L, Zucknick M, Stenzinger A,
Andrulis M, Klauschen F, Joehrens K, Warth A, Renner M,
Mehrabi A, Hafezi M, Thelen A, Schirmacher P, et al.

www.oncotarget.com

23372

Oncotarget

